MX1 - Quarterly Activities Report & Appendix 4C
Filed with ASX · · 12 pages · English
Summary by 6ix AI
The report indicates a significant increase in product sales receipts compared to the previous quarter and outlines a strategic reset focusing on medical CT commercialization. The company has implemented cost-saving measures and received multiple purchase orders for its Rover units, reflecting a growing sales pipeline. Looking ahead, Micro-x expects to benefit from contracted development receipts and a growing Rover sales pipeline, with a commercial release of RoverX planned.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Micro-X
- MX1 - Notice Under Section 708A(5) of the Corporations Act
- Application for quotation of securities - MX1
- Notification of cessation of securities - MX1
- MX1 - Notice of 2026 Annual General Meeting and Proxy Form
- Change of Director's Interest Notice - Patrick O'Brien
Later from Micro-X
All Micro-X news releasesFollow Micro-X into a list and get an email when it puts out news.
Follow Micro-X